首页> 外文OA文献 >A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

【2h】

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

机译：对Sintilimab和Anlotinib的一种显着和耐用的反应，在没有可算是基因组改变的包塑型甲状腺癌的第一线治疗中：案例报告

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lin Gui; Shaoyan Liu; Ye Zhang; Yuankai Shi;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area [J] . Jeon Min Ji, Chun Sung-Min, Kim Deokhoon, Thyroid: official journal of the American Thyroid Association . 2016,第5期

机译：在BRAF（V600E）突变流行区靶向大规模并行测序检测到的变性甲状腺癌的基因组改变。
2. Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib [J] . Laura Leroy, Benjamin Bonhomme, Sylvestre Le Moulec, Thyroid: official journal of the American Thyroid Association . 2020,第2期

机译：在先前用Crizotinib治疗的内塑性淋巴瘤激酶重新排列的共塑性淋巴瘤激酶重新排列的肾盂芳基甲状腺癌的显着反应
3. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma [J] . Godbert Yann, de Figueiredo Benedicte Henriques, Bonichon Francoise, Journal of Clinical Oncology . 2015,第20期

机译：间变性淋巴瘤激酶重排间变性甲状腺癌对克唑替尼的显着反应
4. Global proteomic analysis of ovarian high-grade serous carcinomas using SWATH-MS for targeted verification of proteome changes associated with genomic alterations [C] . Stefani N. Thomas, Jing Chen, Paul Aiyetan, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：卵巢高级浆液癌的全局蛋白质组学分析使用SWATH-MS进行靶向验证与基因组改变相关的蛋白质组变化
5. A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report [O] . Lin Gui, Shaoyan Liu, Ye Zhang, 2021

机译：对Sintilimab和Anlotinib的一种显着和耐用的反应在没有可算是基因组改变的包塑型甲状腺癌的第一线治疗中：案例报告
6. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation [O] . Jian-zhou Cao, Wei Wu, Jin-feng Pan, 2021

机译：案例报告：Anlotinib与Sintilimab相结合作为具有FGFR3突变的转移性尿路上皮膀胱癌患者的第三线治疗

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

著录项

引文网络

相似文献

相关主题

期刊订阅